

# HDAC Inhibitors

## MS-275 (Entinostat)

Preferentially inhibits HDAC1 over HDAC2 and HDAC3 with little to no inhibition of HDAC6/8.<sup>1</sup> Non-hydroxamic acid.

**Product No: 10-2131** 5 mg/ 25 mg/

## Apicidin

Potent, cell permeable pan-specific inhibitor of HDACs.<sup>2</sup>

**Product No: 10-2057** 1 mg/ 5 mg/

## Trichostatin A

Potent and selective pan-specific HDAC inhibitor.<sup>3</sup>

**Product No: 10-2110** 1 mg/ 5 mg/

## BML-210

Novel non-hydroxamic acid HDAC inhibitor with effects on leukemia cell growth, differentiation, and apoptosis.<sup>4</sup>

**Product No: 10-2366** 5 mg/ 25 mg/

## RGFP966

Potent and selective inhibitor of HDAC3.<sup>5</sup>

**Product No: 10-4029** 5 mg/ 25 mg/

## SAHA

Potent and selective pan-specific HDAC inhibitor. Induces apoptosis in a variety of tumor cell lines.<sup>6,7</sup>

**Product No: 10-1067** 50 mg/ 250 mg/

## Tubastatin A HCl

Selective HDAC6 inhibitor.<sup>8</sup>

**Product No: 10-4530** 5 mg/ 25 mg/

## Panobinostat

Clinically useful potent inhibitor of Class I and II HDACs.<sup>9</sup>

**Product No: 10-2157** 5 mg/ 25 mg/

## Romidepsin

Potent and selective inhibitor of Class I HDACs.<sup>10</sup>

**Product No: 10-2365** 1 mg/ 5 mg/

## LMK235

Potent and selective inhibitor of HDAC4 and 5.<sup>11</sup>

**Product No: 10-4024** 5 mg/ 25 mg/

## BG45

BG45 is a potent and selective inhibitor of HDAC3.<sup>12</sup>

**Product No: 10-5638** 5 mg/ 25 mg/

## Santacruzamate A


Ultrapotent non-hydroxamic acid inhibitor of HDAC2.<sup>13</sup>

**Product No: 10-3613** 5 mg/ 25 mg/


## BRD73954

Selective inhibitor of HDACs 6 and 8.<sup>14</sup>

**Product No: 10-4014** 10 mg/ 50 mg/



Trichostatin A



LMK235

## REFERENCES

1. Hu *et al.* (2003) *J. Pharmacol. Exp. Ther.* **307** 720
2. Darkin-Rattray *et al.* (1996) *PNAS* **93** 13143
3. Yoshida *et al.* (1990) *J. Biol. Chem.* **265** 17174
4. Savickiene *et al.* (2006) *Eur. J. Pharmacol.* **549** 9
5. Malvaez *et al.* (2013) *PNAS* **110** 2647
6. Vrana *et al.* (1999) *Oncogene* **18** 7016
7. Butler *et al.* (2002) *PNAS* **99** 11700
8. Butler *et al.* (2010) *J. Am. Chem. Soc.* **132** 10842
9. Geng *et al.* (2006) *Cancer Res.* **66** 11298
10. Furumai *et al.* (2002) *Cancer Res.* **62** 4916
11. Marek *et al.* (2013) *J. Med. Chem.* **56** 427
12. Minami *et al.* (2014) *Leukemia* **28** 680
13. Pavlik *et al.* (2013) *J. Nat. Prod.* **76** 2026
14. Olson *et al.* (2013) *J. Med. Chem.* **56** 4816